Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
We recommend
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses
Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with…
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
Articles on this topic
Dupilumab in the Treatment of Severe Asthma in Real-World Practice
A freshly published French study is the first to confirm the results of clinical trials with…
Treatment of Comorbidities of Atopic Dermatitis in One Go and Where to Refer Candidates for Biologic Therapy
Patients suffering from atopic dermatitis (AD) along with allergic comorbidities typically…
Use of Targeted Therapy with Dupilumab in Patients with Allergic Diseases
Interleukins (IL) 4 and 13 play an important role in the pathogenesis of allergic diseases.…
Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
A new drug is entering the market for the treatment of atopic dermatitis, asthma, and chronic…
Educational Quiz (For Downtime)
The following quiz has been prepared for you as an activity for relaxation and unwinding from today's...
Journal articles Asthma bronchiale in the context of internal medicine
Úvodem poněkud kacířské tvrzení: astma je dnes „dobrá diagnóza“.
Na rozdíl od ostatních nemocí...
Journal articles Skin conditions in patients with inflammatory bowel diseases
Idiopatické střevní záněty (IBD – inflammatory bowel diseases) se mohou manifestovat také na...
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
- Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy
- Skin conditions in patients with inflammatory bowel diseases
- Asthma bronchiale in the context of internal medicine
- Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
- Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Journal on this topic
Related topic